The World Health Organization has confirmed that receiving a Covid-19 vaccine will provide an effective boost of immunity against the disease, but that people must still wear face masks, wash their hands regularly, maintain social distancing, and avoid crowded areas. This is because, despite receiving the vaccine, there is still a chance of contracting Covid-19 from droplets expelled when infected patients cough or sneeze, as well as through contact with their sputum, saliva, and phlegm, for instance.
Patients with underlying health conditions or those who require regular medication should adhere to the following basic advice:
Condition |
Advice |
Coronary artery disease
|
Vaccine can be administered except where acute symptoms present, the condition is unstable, or there are other symptoms that could place the patient in danger. In such cases, the patient’s doctor should make the decision as to whether they are prepared to receive the vaccine. |
Chronic kidney disease requiring dialysis therapy
|
Vaccine can be administered except where acute symptoms present, the condition is unstable, or there are other symptoms that could place the patient in danger. In such cases, the patient’s doctor should make the decision as to whether they are prepared to receive the vaccine. |
Patients who have undergone organ transplant surgery
|
It is recommended to wait at least one month following surgery and to ensure that the condition is deemed stable by the patient’s doctor before the vaccine can be administered. |
Chronic obstructive pulmonary disease / asthma
|
Vaccine can be administered except in cases where acute symptoms present or where the condition is unstable. In such cases, it is recommended to wait 2–4 weeks after any symptoms have improved before the vaccine can be administered. |
Cancer
|
Vaccine can be administered, except in the following circumstances:
|
Diabetes and obesity (Weighing over 100 kg or having a BMI of more than 35/m2)
|
Vaccine can be administered except where acute symptoms occur, or the condition is unstable. |
AIDs
|
Vaccine can be administered except in cases where the infectious disease has just been contracted and therefore requires careful management. |
Rheumatoid arthritis and autoimmune diseases
|
Vaccine can be administered except where acute symptoms occur, or if the condition is unstable. |
Immune neuropathy disorders, such as
|
Vaccine can be administered except in cases where acute symptoms present or where the condition is unstable. In such cases, it is recommended to wait 4 weeks after any symptoms have improved before the vaccine can be administered. |
Cerebrovascular disease
|
Vaccine can be administered except in unstable cases or where symptoms may pose a danger. In such cases, the patient’s doctor should make the decision as to whether the patient is able to receive the vaccine. |
Epilepsy
|
There are no limitations to receiving a vaccine. |
Other neurological disorders, such as Parkinson’s disease, dementia, motor neuron disease, and genetic or age-related musculoskeletal and neuropathy disorders.
|
There are no limitations to receiving a vaccine. |
Medication |
Recommendation |
Corticosteroids (Prednisolone 20 mg; equivalent to Dexamethasone 3 mg and Methylprednisolone 16 mg)
|
For Prednisolone dosage of 20 mg per day or other corticosteroids of equivalent dosage, vaccination may be administered without stopping medications. For a dosage of more than 20 mg per day, or if the patient is in the process of reducing drug dosage, the patient must exhibit stable symptoms before receiving vaccination. |
Immunosuppressants such as Azathioprine, IVIG, and oral route Cyclophosphamide
|
Vaccination may be administered without stopping medications. |
Cyclophosphamide intravenous route
|
Vaccination may be administered if symptoms are stable, with a recommendation to discontinue taking the medication for 1 week following vaccination. |
Mycophenolate
|
Vaccination may be administered if symptoms are stable, with a recommendation to discontinue taking Mycophenolate for 1 week following vaccination. |
Methotrexate
|
Vaccination may be administered if symptoms are stable, with a recommendation to discontinue taking Methotrexate for 1 week following vaccination. |
Hydroxychloroquine, Sulfasalazine, Leflunomide
|
Not necessary to adjust dosage or postpone vaccination. |
Anticoagulant Warfarin
|
Vaccine may be administered to patients with an INR of less than 4, using a 25G or 27G syringe, and the muscle should not be kneaded after vaccination. After vaccination, the injection site should be pressed for 2-5 minutes until it is certain there is no bleeding. |
Antithrombotic agents, such as Fondaparinux
|
Vaccination may be administered, but should be administered before injection of this type of medication. |
Non-Vitamin K Antagonist Oral Anticoagulants (NOAC), such as Dabigatran ,Rivaroxaban, Apixaban and Edoxaban
|
Vaccination may be administered, but a 25G or smaller syringe should be used and the muscle should not be kneaded after vaccination. After vaccination, the injection site should be pressed for at least 2-5 minutes until it is certain there is no bleeding. |
Antiplatet drugs, such as Aspirin, Clopidogrel, Colostazol, Ticagrelor or prasugrel
|
Vaccination may be administered, but a 25G or smaller syringe should be used and the muscle should not be kneaded after vaccination. After vaccination, the injection site should be pressed for at least 2-5 minutes until it is certain there is no bleeding. |
Antibody drugs (drugs ending in -mab)
|
Rituximab: Recommended to administer vaccination 14 days prior to the first dose of this medication or 1 month after taking this drug. Omalizumab, Benralizumab, Dupilumab: Recommended to administer vaccination 7 days before or after taking these medications. |
articles